Skip Navigation



Rheumatology Advance Access published online on October 12, 2004
Rheumatology, doi:10.1093/rheumatology/keh423
Rheumatology © British Society for Rheumatology 2004; all rights reserved
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
44/1/126    most recent
keh423v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bongartz, T.
Right arrow Articles by Müller-Ladner, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bongartz, T.
Right arrow Articles by Müller-Ladner, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received April 16, 2004
Accepted September 2, 2004

Original Papers

Treatment of active psoriatic arthritis with the PPAR{gamma} ligand pioglitazone: an open-label pilot study

T. Bongartz 1*, B. Coras 2, T. Vogt 2, J. Schölmerich 1, and U. Müller-Ladner 1

1 Department of Internal Medicine I, University of Regensburg, Regensburg, Germany
2 Department of Dermatology, University of Regensburg, Regensburg, Germany

* To whom correspondence should be addressed. E-mail: bongartz.tim{at}mayo.edu.


  Abstract

Objectives. Psoriatic arthritis (PsA) is an inflammatory joint disease, in which early neovascularization of affected skin and synovial tissue represents an important pathogenetic step in the disease process. Activation of the peroxisome proliferator activated receptor {gamma} (PPAR{gamma}) showed anti-inflammatory effects in several in vitro and in vivo models (e.g. collagen-induced arthritis) by inhibition of angiogenesis and suppression of proinflammatory cytokines. Therefore, we studied the use of pioglitazone, a PPAR{gamma} agonist originally developed for the treatment of diabetes, in patients with PsA.

Methods. Ten patients with active PsA, seven males and three females, who showed at least two tender and two swollen joints despite stable treatment with an NSAID, were enrolled in this open-label study. All patients received a daily dose of 60 mg pioglitazone while continuing their current NSAID therapy. The primary endpoint was the PsARC (Psoriatic Arthritis Response Criterion); the secondary endpoints included the ACR20 response and improvement in the Psoriasis Area and Severity Index (PASI) in patients with more than 2% skin involvement. Patients were evaluated for endpoints at baseline and after 12 weeks.

Results. After 12 weeks, six of 10 patients met the PsARC. The ACR20 response was achieved in five patients. The mean percentage reduction in PASI was 38%, with a clinically meaningful PASI 50 response in two of six patients. Median tender joint count (interquartile range) decreased from 12.0 (8.0-18.0) to 4.0 (2.0-10.0), and the median swollen joint count from 5.0 (4.0-8.0) to 2.0 (1.0-7.0) (P<0.05 for both). Median Health Assessment Questionnaire score changed from 1.0 (0.375-1.375) to 0.75 (0.375-1.0) (P<0.05). Three patients had to be withdrawn from the study due to inefficacy and side-effects. Major side-effects were oedema of the lower extremities and increase in weight.

Conclusions. Treatment with a PPAR{gamma} agonist appears to be a promising therapeutic principle in PsA, but the use of PPAR{gamma} ligands might be limited by side-effects such as increase in weight and fluid retention.

Keywords: Psoriatic arthritis; Pioglitazone; Peroxisome proliferator activated receptor {gamma} agonists.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.